Zydus Lifesciences Ltd.

Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease

The trial will enrol 164 patients diagnosed with the disease

Zydus Lifesciences soars on inking pact with Apollo Hospitals to expand access to Shield MCD test in India

The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types

Zydus Lifesciences inks pact with Apollo Hospitals to expand access to Shield MCD test in India

The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types

Zydus Lifesciences informs about updates on buy back

Zydus Lifesciences completes $166 million Assertio acquisition

Assertio has become a wholly owned subsidiary of the company

Zydus Lifesciences informs about press release

Zydus Lifesciences soars on reporting 9% rise in Q4 consolidated net profit

Consolidated total income of the company increased by 16.84% at Rs 7,721.20 crore for Q4FY26

Zydus Lifesciences informs about outcome of board meeting

Zydus Lifesciences informs about investor presentation

Zydus Lifesciences reports 9% rise in Q4 consolidated net profit

Consolidated total income of the company increased by 16.84% at Rs 7,721.20 crore for Q4FY26

Zydus Lifesciences reports Profit after tax of Rs 17220.00 Mln, in the March 2026 quarter

Zydus Lifesciences zooms as its arm inks definitive pact to acquire outstanding shares of Assertio

The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions

Zydus Lifesciences’ arm inks definitive pact to acquire outstanding shares of Assertio

The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions

Zydus Lifesciences informs about update on board meeting

Zydus Lifesciences informs about change in director